Prof Enriqueta Felip speaks to ecancer about subcutaneous (SC) versus intravenous (IV) pembrolizumab plus chemotherapy (CT) in metastatic non-small cell lung cancer (mNSCLC).

This phase 3 MK-3475A-D77 trial examines untreated stage four non-small cell lung cancer patients receiving either subcutaneous or IV pembrolizumab with chemotherapy.

The trial meets its primary endpoints, showing that subcutaneous pembrolizumab is non-inferior to the IV formulation.

Both treatments yield similar progression-free survival and response rates, with comparable adverse events.

The study concludes that subcutaneous pembrolizumab is a viable treatment option.